Last Updated: September 23, 2026
A 340B contract pharmacy agreement lets a covered entity dispense 340B drugs through a community pharmacy while a TPA handles claims, replenishment, and reconciliation. Its clauses decide who carries the risk when a payer takes money back or the relationship ends.
Use this checklist before signing or renewing any pharmacy services agreement (PSA).
| Clause | What to Ask For | Why It Matters |
|---|---|---|
| Termination | 60-day no-cause notice, both directions | Lets the entity exit without proving fault |
| Exclusivity | No exclusivity clause; patient choice preserved | Patients keep their pharmacy; entity keeps flexibility |
| Payment terms | Step-down from 90 to 30 days over first months | Speeds cash without a permanent 90-day drag |
| Withhold reserve | Sized in writing, releasable on request | Prevents the pharmacy holding margin indefinitely |
| Disbursement | Monthly payment plus quarterly reconciliation | Matches cash to claims, not to estimates |
| Retroactive adjustments | Defined window and shared liability | Payer takebacks are real; someone must own them |
| Inventory | Written settlement method at exit | Physical-inventory models can leave loan balances |
| Data transfer | File format and deadline on exit | Claims history belongs to the entity |
| Post-termination audit | 2-year window, both parties | Protects against late findings |
| Dispute path | Named escalation steps and timelines | Avoids litigation over small variances |
The termination clause is the one operators regret most. A 60-day no-cause right in both directions gives the covered entity a real exit; without it, leaving means proving breach.
Payment terms set the pace of cash. A step-down from 90 to 30 days over the first few months is common and worth asking for.
The 340B contract pharmacy termination clause should give the covered entity a 60-day no-cause exit, a defined withhold reserve true-up, and a data transfer deadline. Sequencing matters more than the notice period.
Run the 340B pharmacy reconciliation process on both a cash and an accrual basis every month. Reading only one hides where the margin sits.
| Statement View | What It Shows | What to Do |
|---|---|---|
| Cash basis | Cumulative over/under position | Check for advance liabilities |
| Accrual basis | Margin held in trailing A/R | Reconcile to claims, not estimates |
| Quarterly | True-up against actuals | Compare to monthly totals |
Risk mitigation clauses decide who pays when a HRSA audit finds a duplicate discount, a manufacturer demands repayment, or a payer takes back a claim two quarters later. Most PSAs describe these events in one sentence and leave allocation to negotiation after the fact, the wrong time to negotiate.
Indemnification should run both ways and tie to each party's own conduct, not the audit outcome. A one-way clause making the entity indemnify the pharmacy for "any 340B-related liability" shifts risk the entity cannot control.
The audit trail clause should name the data elements, retention period, and format. "Reasonable records" is not a clause; it is a future dispute.
| Data Element | Retention | Format on Request |
|---|---|---|
| Claim-level prescription records | 2 years post-termination (align to HRSA audit window) | CSV or flat file, claim-level |
| 340B ID and prescriber NPI on each claim | Same | Same |
| Replenishment and accumulator records | Same | Same |
| Remittance and dispensing fee detail | Same | Same |
| Medicaid Exclusion File match confirmation | Same | Same |
| Duplicate discount screening logs | Same | Same |
A confidentiality clause does not cover PHI. The agreement needs an executed HIPAA business associate agreement (BAA) before any PHI moves, naming permitted uses, the breach notification timeline, and subcontractor flow-down.
This section is general information, not legal advice. Covered entities should have counsel review indemnification, BAA, and audit-trail language before signing.
Negotiation use comes from volume, term length, and the threat of a clean exit. Covered entities have more of it than they use.
Performance metrics turn a vague agreement into an enforceable one. The gap in most PSAs is not the metric list but the absence of thresholds, remedies, and a named owner on each side. A KPI without a remedy is a suggestion.
| KPI | Threshold to Ask For | Remedy if Missed |
|---|---|---|
| Remittance turnaround | Within stated payment terms (target step-down 90 to 30 days) | Interest or offset against next disbursement |
| Reconciliation accuracy | Variance under an agreed threshold, reconciled to claims not estimates | Entity right to request a true-up within 30 days |
| Claim rejection rate | Under an agreed ceiling, tracked monthly | Root-cause report from pharmacy within 15 days |
| Dispute resolution | Response within a defined window (e.g., 10 business days) | Escalation to named executive on each side |
| Data transfer on exit | By a stated deadline in a stated format | Withhold reserve release conditioned on delivery |
| Withhold reserve true-up | On request, within a stated window | Entity right to offset |
| 340B ID and prescriber NPI accuracy on claims | 100% match to entity roster | Claim-level correction and resubmission |
| Medicaid Exclusion File screening | Every claim, logged | Entity right to audit and to terminate for cause |
Every PSA lists "timely remittance" and "accurate reconciliation." Almost none define "timely" or "accurate." That is where the leverage disappears.
The quarterly review is the enforcement mechanism. It needs a named contact on each side, a standing agenda, and authority to trigger a pricing review or termination notice.
This section is general information, not legal advice. Covered entities should have counsel review KPI schedules and remedy language before signing.
Pharmacy agreements fail quietly, through a reserve that never releases or a termination clause that runs one way. The clauses above decide whether a 340B program keeps its margin or funds someone else's cash flow.
It is a written agreement between a covered entity and an independent pharmacy that lets the pharmacy dispense 340B drugs to the entity's eligible patients on the entity's behalf. The pharmacy submits prescription claims, replenishes inventory, and remits the difference between the 340B ceiling price and what the payer reimbursed. It is not a purchase order; it is a compliance document. HRSA expects the covered entity to keep oversight, an audit trail, and a HIPAA business associate agreement in place.
In agreements we review, 60-day no-cause termination is common, with shorter windows for cause such as a material compliance breach. What matters more than the notice period is what happens after notice: inventory loan settlement, release of the withhold reserve, data transfer on exit, and how long the pharmacy keeps post-termination audit rights. Ask for a written true-up of the reserve at notice, not at the end of the tail.
Retroactive adjustments are where most disputes start. Ask for a defined lookback window, a per-claim line item for every reversal, and a cap on how far back the pharmacy can claw back. Read the monthly statement on both a cash basis and an accrual basis: cash ledgers can show the clinic owing the pharmacy while accrual shows the pharmacy holding clinic margin in trailing insurer A/R. Reconcile by drug class, not just in total.
A withhold reserve is money the pharmacy holds back from disbursements to cover potential payer reversals or duplicate discount exposure. Ask for the reserve to be sized in writing, tied to a stated formula, and releasable on request after reconciliation. Without a release mechanism, the reserve can sit indefinitely. In our experience, most pharmacy services agreements allow a request for true-up, but only if you ask in writing and track the balance.
Yes. Nothing in the 340B drug pricing program limits a covered entity to one contract pharmacy, though manufacturer restrictions may limit which drugs can be shipped to which locations. The practical constraint is oversight: every additional pharmacy adds a reconciliation report, an audit trail, and a HIPAA business associate agreement to manage. Keep one owner for the pharmacy roster and review net-per-claim by drug class before adding another site.
Bring us your patient acquisition, 340B program, or compliance bottleneck. We will show you what a 30-day launch looks like for your clinic — in English or Spanish, month to month, no long contract.
